RDP-58 (SangStat Medical).
RDP-58, a decapeptide with inhibitory effects on tumor necrosis factor synthesis, is under development by SangStat Medical Corp for the potential treatment of Crohn's disease and ulcerative colitis; phase II trials for both these indications commenced in October 2001. SangStat also initiated a phase I trial in chemotherapy-induced diarrhea in the first quarter of 2003 and anticipates initiating phase I trials in the gastrointestinal complications of HIV by the end of 2003.
Holtmann
Martin M
MM
1st Department of Medicine, Johannes Gutenberg-University, Langenbeckstrasse 1, 55 131 Mainz, Germany. mholtman@mail.uni-mainz.de
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003093:Colitis, Ulcerative / Q000188:drug therapy; D003424:Crohn Disease / Q000188:drug therapy; D006801:Humans; D010455:Peptides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010455:Peptides; C092373:allotrap